CERO THERAPEUTICS HOLDINGS, INC. (CERO) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
CERO THERAPEUTICS HOLDINGS, INC. (CERO) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
CERO THERAPEUTICS HOLDINGS, INC. (Stock Symbol: CERO)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $3 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for CERO THERAPEUTICS HOLDINGS, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
CERO THERAPEUTICS HOLDINGS, INC. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
CERO THERAPEUTICS HOLDINGS, INC. Stock Price Chart and Technical Analysis
Loading chart data...
Loading CERO THERAPEUTICS HOLDINGS, INC. interactive price chart and technical analysis...
Deep dive into CERO THERAPEUTICS HOLDINGS, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if CERO THERAPEUTICS HOLDINGS, INC. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For CERO THERAPEUTICS HOLDINGS, INC.:
P/B Ratio-196.22x
Market Cap$3M
Book Value/Share$-56.35
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently CERO THERAPEUTICS HOLDINGS, INC. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For CERO THERAPEUTICS HOLDINGS, INC.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess CERO THERAPEUTICS HOLDINGS, INC.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For CERO THERAPEUTICS HOLDINGS, INC.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal CERO THERAPEUTICS HOLDINGS, INC.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For CERO THERAPEUTICS HOLDINGS, INC.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively CERO THERAPEUTICS HOLDINGS, INC. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For CERO THERAPEUTICS HOLDINGS, INC.:
Understanding Financial Statement Data
What these metrics mean: Key figures from CERO THERAPEUTICS HOLDINGS, INC.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For CERO THERAPEUTICS HOLDINGS, INC.:
Income Statement ($ Millions)
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding0M
CERO THERAPEUTICS HOLDINGS, INC. (CERO) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for CERO THERAPEUTICS HOLDINGS, INC. stock analysis.
Loading fundamental data...
Loading CERO THERAPEUTICS HOLDINGS, INC. comprehensive fundamental analysis and insider trading data...
Latest CERO THERAPEUTICS HOLDINGS, INC. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting CERO THERAPEUTICS HOLDINGS, INC. (CERO) stock price and investment outlook.
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc ...
--CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has ...
About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer.
SOUTH SAN FRANSCISCO, Calif., June 11, 2025-- CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that ...
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting CERo Therapeutics Holdings, Inc ...
SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (CERO), (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance ...
News CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) GlobeNewswire Jun 17, 2025, 5:15:00 AM ...
Home News GlobeNewswire CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 ...
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect ...
A high-level overview of CERo Therapeutics Holdings, Inc. WT EXP 090126 (CEROW) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
CERO THERAPEUTICS HOLDINGS, INC. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of CERO THERAPEUTICS HOLDINGS, INC. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - CERO THERAPEUTICS HOLDINGS, INC. Stock Forecast
How accurate are CERO THERAPEUTICS HOLDINGS, INC. stock predictions?
Our AI model demonstrates -6% historical accuracy for CERO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence CERO THERAPEUTICS HOLDINGS, INC. stock price forecasts?
Is CERO THERAPEUTICS HOLDINGS, INC. a good investment in 2025?
Based on our AI analysis, CERO THERAPEUTICS HOLDINGS, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are CERO THERAPEUTICS HOLDINGS, INC. forecasts updated?
CERO THERAPEUTICS HOLDINGS, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced CERO THERAPEUTICS HOLDINGS, INC. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for CERO THERAPEUTICS HOLDINGS, INC. stock.
